HOME >> BIOLOGY >> NEWS
UF Researcher: Global warming dramatically changed ancient forests

tion, in the Bighorn Basin of northwestern Wyoming uncovered fossil leaves and pollen alongside fossilized mammals in rocks that were deposited during this turbulent geologic interval.

"Up until this point we have not had a place in which we have mammal and plant remains preserved in the same rocks spanning what we call the Paleocene-Eocene boundary," Bloch said. "Amazingly, these plants came from what would have been more tropical environments."

Some of the plant remains resembled those found in rock deposits of similar age unearthed in Mississippi, Louisiana and Texas, including relatives of poinsettia and sumac, Bloch said.

However, plant fossils found in the same area dating immediately before and after this period of rising temperatures reflected typical mid-latitude forests of the time and included relatives of dawn redwood, alder, sycamore and walnut, Bloch said. As temperatures cooled, floral newcomers appeared from Europe, including species of linden and wing nut. These plants probably emigrated along the same land bridges that animals traveled, he said.

Because his research specialty is mammals, Bloch said he is particularly interested in understanding how the movement of plants affected the earliest evolution of modern primates, which first appeared throughout the world during this period.

"I would very much like to know what these forests were like when these first modern primates were coming in because it has implications for how these animals lived and behaved right from the beginning," he said.

If the landscape evolved from an initially drier habitat, with patchy open spaces, into a more lush tropical forest with densely packed trees, it might have played a role in the evolution of primates' climbing skills, Bloch said. The ancestors of living primates would have been leaping through the tree canopy, foraging for fruit and insects, he said.

Partly because of the dramatic change in mammals, including the first appea
'"/>

Contact: Jonathan Bloch
jbloch@flmnh.ufl.edu
352-392-1721
University of Florida
10-Nov-2005


Page: 1 2 3

Related biology news :

1. Researcher: Toxic flood lifts lid on common urban pollution problem
2. Global community listens to TAU genetic researcher at EU Conference on Hearing Loss
3. Global warming is evaporating Arctic ponds, new study shows
4. Global heartbeat control suggests therapy for beating heart failure
5. Global survey of lizards reveals greater abundance of animals on islands than on mainland ecosystems
6. Global ocean sampling expedition
7. Global Nephrology gathers in Rio
8. Global study concludes attack rate of flu in kids is 55 percent lower with nasal spray vaccine
9. Global warming of the future is projected by ancient carbon emissions
10. Global warming is reducing ocean life, increasing atmospheric carbon dioxide, say scientists
11. Global warming will reduce ocean productivity, marine life

Post Your Comments:
(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
Cached News: